Royalty Pharma plc

NasdaqGS:RPRX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💰 Investment Banking & Asset Management

💊 Pharmaceuticals

💰 Venture Capital

Location

United States

Market Cap

USD 20.32 B

Share Price

USD 36.14

Avg Daily Volume

4,950,160

Change (1 day)

2.09%

Change (1 year)

33.31%

Change (YTD)

41.67%

Royalty Pharma plc Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 2.26 B

Royalty Pharma plc Revenue is USD 2.26 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 1.15% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Royalty Pharma plc Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 2.24 B, a -5.11% change year over year.
Royalty Pharma plc Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 2.36 B, a 3.54% change year over year.
Royalty Pharma plc Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 2.28 B, a 3.85% change year over year.
Royalty Pharma plc Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 2.19 B, a 16.68% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NasdaqGS: RPRX

Royalty Pharma plc

CEO	Mr. Pablo Gerardo Legorreta
IPO Date	June 16, 2020
Location	United States
Headquarters	110 East 59th Street
Employees	75
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💰 Investment Banking & Asset Management 💊 Pharmaceuticals 💰 Venture Capital

Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.